Cargando…

Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review

Posterior reversible encephalopathy syndrome (PRES) is a relatively rare clinical disease, characterized by reversible subcortical vasogenic edema. Here, we present the first reported case of PRES induced by anlotinib, a multi-target tyrosine kinase inhibitor. A 56-year-old female patient with lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Nan, Di, Yin, Xiang, Ma, Di, Jiang, Xiaoyu, Wu, Baihua, Feng, Jiachun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134686/
https://www.ncbi.nlm.nih.gov/pubmed/34025545
http://dx.doi.org/10.3389/fneur.2021.546481
_version_ 1783695219470893056
author Nan, Di
Yin, Xiang
Ma, Di
Jiang, Xiaoyu
Wu, Baihua
Feng, Jiachun
author_facet Nan, Di
Yin, Xiang
Ma, Di
Jiang, Xiaoyu
Wu, Baihua
Feng, Jiachun
author_sort Nan, Di
collection PubMed
description Posterior reversible encephalopathy syndrome (PRES) is a relatively rare clinical disease, characterized by reversible subcortical vasogenic edema. Here, we present the first reported case of PRES induced by anlotinib, a multi-target tyrosine kinase inhibitor. A 56-year-old female patient with lung adenocarcinoma and bone metastasis experienced hypertension and mental confusion when she received anti-angiogenesis treatment. PRES was diagnosed after magnetic resonance of the patient's brain revealed hyperintensities bilaterally around the cerebellum, pons, fronto-parieto-occipital areas, and corona radiate. Diffusion-weighted imaging showed hyperintensities bilaterally in the parieto-occipital cortical regions. Subsequently, the patient was diagnosed with PRES, and remission was achieved with anti-hypertensive drugs. Six cases of rare adverse effects induced by anlotinib were reviewed in the literature. Since anlotinib has been widely applied as a novel third-line treatment in patients with non-small-cell lung cancer, the association between PRES and anlotinib would benefit neurologists and oncologists in future diagnoses and treatment.
format Online
Article
Text
id pubmed-8134686
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81346862021-05-21 Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review Nan, Di Yin, Xiang Ma, Di Jiang, Xiaoyu Wu, Baihua Feng, Jiachun Front Neurol Neurology Posterior reversible encephalopathy syndrome (PRES) is a relatively rare clinical disease, characterized by reversible subcortical vasogenic edema. Here, we present the first reported case of PRES induced by anlotinib, a multi-target tyrosine kinase inhibitor. A 56-year-old female patient with lung adenocarcinoma and bone metastasis experienced hypertension and mental confusion when she received anti-angiogenesis treatment. PRES was diagnosed after magnetic resonance of the patient's brain revealed hyperintensities bilaterally around the cerebellum, pons, fronto-parieto-occipital areas, and corona radiate. Diffusion-weighted imaging showed hyperintensities bilaterally in the parieto-occipital cortical regions. Subsequently, the patient was diagnosed with PRES, and remission was achieved with anti-hypertensive drugs. Six cases of rare adverse effects induced by anlotinib were reviewed in the literature. Since anlotinib has been widely applied as a novel third-line treatment in patients with non-small-cell lung cancer, the association between PRES and anlotinib would benefit neurologists and oncologists in future diagnoses and treatment. Frontiers Media S.A. 2021-05-06 /pmc/articles/PMC8134686/ /pubmed/34025545 http://dx.doi.org/10.3389/fneur.2021.546481 Text en Copyright © 2021 Nan, Yin, Ma, Jiang, Wu and Feng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Nan, Di
Yin, Xiang
Ma, Di
Jiang, Xiaoyu
Wu, Baihua
Feng, Jiachun
Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review
title Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review
title_full Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review
title_fullStr Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review
title_full_unstemmed Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review
title_short Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review
title_sort posterior reversible encephalopathy syndrome associated with anlotinib: a case report and literature review
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134686/
https://www.ncbi.nlm.nih.gov/pubmed/34025545
http://dx.doi.org/10.3389/fneur.2021.546481
work_keys_str_mv AT nandi posteriorreversibleencephalopathysyndromeassociatedwithanlotinibacasereportandliteraturereview
AT yinxiang posteriorreversibleencephalopathysyndromeassociatedwithanlotinibacasereportandliteraturereview
AT madi posteriorreversibleencephalopathysyndromeassociatedwithanlotinibacasereportandliteraturereview
AT jiangxiaoyu posteriorreversibleencephalopathysyndromeassociatedwithanlotinibacasereportandliteraturereview
AT wubaihua posteriorreversibleencephalopathysyndromeassociatedwithanlotinibacasereportandliteraturereview
AT fengjiachun posteriorreversibleencephalopathysyndromeassociatedwithanlotinibacasereportandliteraturereview